NCT00234494 - Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions

Bladder Cancer

Interventions

DRUG

Cisplatin

Cisplatin 70 mg/m2, day 1

DRUG

Gemcitabine

Gemcitabine 1250 mg/m2, day 1 and 8

DRUG

Bevacizumab

Bevacizumab 15mg/kg, day 1

Trial Locations (11)

Oncology Hematology Care, Inc., Cincinnati

Indiana University Cancer Center, Indianapolis

Quality Cancer Center (MCGOP), Indianapolis

Northern Indiana Cancer Research Consortium, South Bend

Fort Wayne Oncology & Hematology, Inc, Fort Wayne

Oncology Hematology Associates of SW Indiana, Evansville

AP&S Clinic, Terre Haute

Arnett Cancer Care, Lafayette

University of Chicago, Chicago

Medical & Surgical Specialists, LLC, Galesburg

Siteman Cancer Center, St Louis